46740
document
Niacin revisited . A randomized , controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia . Two hundred one male and female subjects , aged 20 to 70 years , with elevated low-density lipoprotein cholesterol values ( in the 75th to 95th percentiles ) , participated in a randomized , controlled , double-blind study using a new form of niacin ( Enduracin ) , which employs a wax-matrix vehicle for sustained release . Four niacin treatment groups ( daily doses of 2000 , 1500 , 1250 , and 1000 mg ) were compared with placebo- and diet-treated controls to determine side-effect profile and optimal range of efficacy . The groups given 2000 and 1500 mg demonstrated significant reductions in values of low-density lipoprotein cholesterol ( -26 % and -19.3 % , respectively ) , total cholesterol ( -18.4 % and -13.3 % ) , and total cholesterol-high-density lipoprotein cholesterol ratio ( -20.4 % and -19.4 % ) when compared with diet- and placebo-treated controls . Smaller improvements were seen in high-density lipoprotein cholesterol and triglyceride levels . Blood chemistry monitoring indicated that reduction in low-density lipoprotein cholesterol level strongly correlated with an increase in baseline levels of some enzymes for niacin-treated subjects . The improved side-effect profile of the wax-matrix form of niacin was particularly notable . The dropout rate due to side effects was only 3.4 % and was coupled with good medication compliance .
46741
Intervention_Pharmacological
Niacin
46742
Intervention_Pharmacological
wax-matrix sustained-release niacin
46743
Intervention_Pharmacological
niacin ( Enduracin )
46744
Intervention_Pharmacological
niacin
46745
Intervention_Control
placebo- and diet-treated controls
46746
Intervention_Pharmacological
niacin
46747
Outcome_Physical
hypercholesterolemia .
46748
Outcome_Physical
low-density lipoprotein cholesterol
46749
Outcome_Physical
total cholesterol
46750
Outcome_Physical
total cholesterol-high-density lipoprotein cholesterol ratio
46751
Outcome_Physical
high-density lipoprotein cholesterol and triglyceride levels .
46752
Outcome_Physical
low-density lipoprotein cholesterol level
46753
Outcome_Other
dropout rate
46754
Outcome_Adverse-effects
side effects
46755
Participant_Condition
hypercholesterolemia
46756
Participant_Sample-size
Two hundred one
46757
Participant_Age
20 to 70
46758
Participant_Condition
elevated low-density lipoprotein cholesterol values ( in the 75th to 95th percentiles )